Results From the Phase III AUGMENT Trial in Recurrent Indolent Lymphomas

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination of lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

The primary endpoint of this trial was progression-free survival (PFS). In the combination arm, PFS was 39 months compared to 14 months in the rituximab alone arm, Leonard says.

In addition to this significant increase in duration of PFS, there was also an improvement in both the response rate and complete remission rate. Leonard says there was also overall survival benefit in patients with follicular lymphoma.

See more on thedata from the AUGMENT trial